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ABSTRACT 
Malaria is the most prevalent tropical human disease reported worldwide, caused 
by protozoan parasites. Half of the world's population is at risk of malaria, and 
more than 200 million new cases are reported annually. Currently, there are no 
licensed vaccines available for use. Therefore, there is a vital need for 
developing an effective and reliable anti-malaria vaccine ideally protecting 
different parasitic infection stages comprising different antigens that generate 
appropriate cell-mediated antibody responses of the parasite presentation. Plant-
based vaccines serve as novel platforms for developing safe, reliable, and 
affordable treatments. 
In this study, a Malchloroplast candidate vaccine is designed, comprised of 
segments of AMA-1 and MSP-1 proteins along with the GK1 peptide form Teania 
solium as adjuvant, and expressed in tobacco chloroplasts. Transplastomic 
tobacco lines have been generated using biolistic transformation, and these are 
confirmed to carry the synthetic gene construct. The synthetic GK1 peptide is 
confirmed to be expressed using RT-PCR and Western blots, and detected by 
RP-HPLC at levels of up to 6 µg g-1 dry weight of tobacco leaf tissue. The plant-
derived Malchloroplast candidate vaccine components have been recognized by 
antibodies in Plasmodium falciparum Malaria patients, and has elicited specific 
antibodies in subcutaneously immunized BALB/c mice.  
Additionally, a peptide-based vaccine, Mvac, targeting the MSP1 and AMA1 
antigens was evaluated in combination with different adjuvants in an oral and 
subcutaneous immunization scheme applied to BALB/c mice. Adjuvants tested 
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were plant DNA, pectin, β-subunit of cholera toxin and the GK1 peptide from T. 
solium. Neither plant DNA nor pectin enhanced the humoral response induced 
against the Mvac components. While, GK1 peptide had exerted adjuvant effects 
in terms of the systemic IgG responses induced against the AMA1 peptide, 
although pectin enhanced the IgA intestinal secretion against both MSP1 and 
AMA1 antigens. 
Overall our findings suggest that a multi-component plant-based vaccine against 
malaria expressing AMA1 and MSP1 antigens, and the GK1 peptide has the 
potential to serve as a viable and promising low-cost vaccine. As well as oral 
administration of a vaccine with GK1 peptide has a promising immunogenic 
effects, proposing that a plant-based vaccine against Malaria administered orally 
can be effective. 
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CHAPTER 1 
Literature Review 
INTRODUCTION 
Malaria is a potentially deadly tropical disease, with worldwide estimates of 200 
to 300 million malaria infections reported annually, causing nearly a million 
deaths, mostly of children under 5 years of age. In 2013, approximately 100 
countries were reported to be endemic for malaria with 45 in the African region 
[1]. About 1,200 cases of malaria are diagnosed in the United States each year.   
These cases are primarily from persons entering the country for the first time or 
returning back from foreign travel [2]. 
It has been over 135 years since the French physician Dr. Charles Louis 
Alphonse Laveran first observed on malaria protozoan parasites observed under 
the microscope, and more than 110 years since Ronald Ross and Giovanni 
Grassi identified the mosquito as the vector for malaria transmission [3]. 
Since then, there have been many significant developments in malaria research 
These include unraveling the complex life cycle of the parasite; development of 
anti-malarial drugs and insecticides; discovery of “malaria therapy” for tertiary 
syphilis (in which the fever associated with malaria killed the heat-sensitive 
Treponema pallidum organism responsible for syphilis); development of malarial 
drug resistance; cloning of malaria genes; and recently early phase vaccine trials 
[4]. 
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Malaria is caused by any one of four species of parasites, belonging to the 
Plasmodium genus. Although there are dozens of species of malaria parasites, 
those that infect humans are limited to Plasmodium falciparum, P. vivax, P. 
ovale, and P. malariae.  Among these, P. falciparium and P. vivax are the most 
common, and P. falciparum is potentially life-threatening [5]. Plasmodium 
parasites infect mosquitoes of the genus Anopheles. The main mosquito vectors 
for human transmission are Anopheles gambiae and Anopheles stephensi [6]. 
Plasmodium falciparum 
The Plasmodium life cycle begins in the mosquito. When ingested red blood cells 
(erythrocytes)(RBCs) from a malaria-infected human first burst, released 
gametocytes produce gametes. Male gametocytes undergo divisions to produce 
around eight male gametes that are exflagellated. Female gametocytes within a 
mosquito are transformed into female gametes.  Subsequently, fusion of a male 
gamete and a female gamete results in a zygote, which then develops into an 
ookinete. The motile ookinete migrates into the mosquito’s midgut epithelium to 
initiate formation of an oocyst.  Multiple divisions by the oocyst end in the 
production of thousands of sporozoites, which in turn migrate to salivary glands, 
and are then injected into a fresh human host during the next blood meal of the 
Anopheles [7, 8].  Sporozoites enter the human bloodstream and quickly invade 
liver cells. However, these sporozoites are cleared from the blood within a period 
of 30 minutes. During the next 14 days, liver-stage parasites differentiate and 
undergo asexual multiplication, resulting in tens of thousands of merozoites that 
are released from hepatocyte cells. Individual merozoites invade erythrocytes, 
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and undergo an additional round of multiplication, producing 12 to 16 merozoites 
within a single schizont, Thus, mature parasites are formed, and containing many 
merozoites [9]. 
Malaria disease and current treatment protocols 
Clinical manifestations of the malaria disease, including fever and chills, are 
associated with the synchronous rupture of the infected erythrocyte. The 
released merozoites go on to invade additional erythrocytes. RBC rupture also 
contributes to anemia associated with malaria [10]. Other clinical features include 
headaches, muscular pain and weakness, coughing, vomiting, abdominal pain, 
and diarrhea. These initial symptoms, which are usually mild, may not be readily 
recognizable as malaria.  If a treatment is not administered accordingly, more 
severe complications of malaria can occur. Most people can develop 
complications, such as brain tissue injury, causing extreme sleepiness, 
unconsciousness, convulsions, and even comas, as well as kidney failure, 
severe anemia, and jaundice [11]. 
Most countries with incidence of P. falciparum malaria have adopted Artemisin-
based combination therapies (ACT) as a first-line of treatment.  The World Health 
Organization (WHO) recommends that uncomplicated P. falciparum malaria 
should be treated with an ACT in areas where chloroquine remains effective.  
ACT is a combination of a rapidly acting artemisinin derivative with a longer-
acting (more slowly eliminated) partner drug. The mode of action of this 
treatment combination is attributed to the fact that artemisinin quickly clears 
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parasites from the blood stream, and it is active against sexual stages of the 
parasite that mediate further transmission to mosquitos. The longer acting 
partner drug will clear all remaining parasites, and deliver protection against 
development of resistance to the artemisinin derivative [12].  Studies on drug 
efficacy have reported incidence of P. falciparum resistance to artemisinins in 
five countries, including Cambodia, the Lao People’s Democratic Republic, 
Myanmar, Thailand, and Vietnam. Despite changes in sensitivity of the parasite 
to artemisinins in these countries, ACTs have generally remained clinically and 
parasitologically effective [1].  
Vaccines are expected to serve as promising tools for malaria prevention and 
control. To date, there is no safe and effective malaria vaccine available for field 
use. An ideal malaria vaccine should control the parasite in pre-erythrocytic and 
blood stages and possess transmission-blocking activities. However, progress 
towards an efficacious vaccine has been slow, due to the high polymorphism of 
prospective target antigens and the inability of most vaccines to elicit long-lived 
immunological activities within the host [13]. 
Malaria vaccine development 
Vaccination is a successful method for disease control and prevention of disease 
spread.  There are numerous vaccine success stories, the most notable being 
the eradication of smallpox and the virtual elimination of polio. Many factors 
conspire to render the development of a malaria vaccine a challenging effort. An 
important factor impeding vaccine development is the complex biology of the life 
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cycle of the parasite, which exists in different forms (and each form having a 
different pattern of antigen expression) in different tissues of the human body and 
that of the mosquito. These various forms of the parasite are susceptible to 
immune attack, although the type of immune response required is very different 
for each form. Therefore, it is likely that various vaccine strategies should be 
considered.  
A second factor that impedes vaccine development is the ability of the malaria 
parasite to alter itself.  Antigenic variation and allelic polymorphism are important 
obstacles to subunit vaccine development, especially given that many of the 
amino acid sequence alterations in malaria proteins occur in regions that are 
critical to immunity.  Other factors impeding malaria vaccine development include 
the following: immunological non-responsiveness of certain individuals 
(depending on their human leukocyte antigen and other antigens) to proteins that 
might comprise a vaccine [14]; clonal imprinting or where the original antigenic 
response is influenced by stochastic events and prior exposure to other, perhaps 
cross-reactive antigens [15, 16, 17]; difficulties encountered in proper folding of 
recombinant subunit vaccines to maintain their immunogenic properties; lack of 
suitably potent adjuvants necessary to induce high-titre antibody responses; and 
lack of animal/parasite systems that adequately model the human condition and 
the malaria parasite, pertaining to disease pathogenesis and immunological 
responses. 
Most vaccines that have been developed for various diseases have relied on the 
“simple” approach of presenting the entire antigenic compartment of the 
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organism in the form of either a killed or a living but an attenuated organism [4]. 
Such vaccine approaches are not feasible at present for malaria, as the organism 
grows within RBCs in the mammalian host. Although in vitro culture of the 
organism is possible, a source of RBCs is required.  Therefore, it is impractical 
and potentially unsafe to consider growing a vaccine in human RBCs for a 
disease for which 40% of the world’s population is potentially at risk. Malaria 
vaccine development has therefore focused on the development of the use of a 
subunit vaccine. 
Current approaches toward developing anti-malaria vaccines 
Considerable interest has been focused on the identification of potential protein 
candidates for the development of vaccine production. Several proteins have 
been identified as targets for protective immune responses. Studies of pre-
erythrocyte stage synthetic vaccines consisting of unmodified circumsporozoite 
protein (CSP) amino acid sequences have yielded negative results [18]. Yet, in 
another vaccination assay involving a thrombospondin-related protein (TRAP), 
which was inserted into genetically modified vectors such as fowl pox (FP9) and 
the modified vaccinia virus (MVA), disappointing negative results were reported 
[19, 20, 21]. 
In another attempt at developing a vaccine against malaria, a circumsporozoite 
protein, RTS,S/AS02A, the only sporozoite stage vaccine candidate, has 
provided only partial protection. Similarly, a merozoite stage vaccine NYVAC-7 
(containing genes encoding seven molecules derived from different parasite 
proteins) protected only one out of 35 vaccinated volunteers [22].   
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RTS,S (also known as MosquirixTM) is the one malaria vaccine candidate that is 
in advanced development by GlaxoSmithKline  (GSK) and the Program for 
Appropriate Technology in Health Malaria Vaccine Initiative (MVI), with  funding 
from the Bill & Melinda Gates Foundation.  A phase III clinical trial, involving 
15,459 infants and young children from different sites in seven countries, has 
been conducted in Africa to test efficacy and safety of RTS,S. . Final results from 
this large-scale trial of the RTS,S malaria vaccine candidate, including the impact 
of a booster dose,  have demonstrated that the vaccine candidate protects 
children and infants from clinical malaria for at least three years following the first 
vaccination.  These promising results may yield the first licensed vaccine against 
malaria. If the RTS,S vaccine is approved for administration, GSK has committed 
to making the vaccine available at a ‘not-for-profit’ price that would benefit 
malaria endemic areas in developing countries where the prevalence of the 
disease is high [23]. 
Among the most broadly studied blood-stage vaccine antigens are merozoite 
surface protein 1 (MSP1) and the apical membrane antigen 1 (AMA1).  With its 
presence on the surface of all known Plasmodium spp., MSP1 is a polypeptide of 
190–230 kDa that undergoes processing during schizont rupture to produce at 
least four distinct fragments, 83, 28 to 30, 38, 45, and 42 kDa in size. Further 
cleavage of the carboxy-terminal 42-kDa (MSP142) fragment yields a 19-kDa 
fragment (MSP119), in a process that appears to be critical for merozoite invasion 
[24, 25].  Several reports have highlighted the role of a full-length Merozoite 
surface protein 1 (MSP1) as well as the C-terminal 19 kDa region of MSP1 
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(MSP119) in providing protection against malaria infection, as MSP119 itself 
provides protection in both mice [26] and monkeys [27].  AMA1, which is also 
expressed during sporozoite and hepatic stages, has demonstrated protective 
efficacy in rodent and simian models, indicating that AMA1 is an important target 
of naturally acquired protective antibodies in humans [28, 29, 30]. Antigenic 
diversity of AMA1 that can mediate immune escapes, and immunization attempts 
in animal models have been found to  typically protective against homologous 
parasite challenge, but with reduced protection against heterologous strains 
[31,32]. The capacity of AMA1 to elicit protective immunity in humans has been 
recently demonstrated by a phase 2b vaccine trial of 1 to 6 year-old children in 
Mali [33].  Some integral membrane proteins of the merozoite surface, such as 
MSP1 [34], MSP2 [35], and MSP4 [36] have also been tested.   
A mixture of MSP1 and MSP2 formulated in an oil-based adjuvant did not 
produce significant levels of protection in vaccinated individuals [37, 38].  A 
phase I clinical study for multicomponent blood stage antigens MSP1 and AMA1 
with alhydrogel, used as an adjuvant, of adults in the U.S. and in Mali has been 
conducted, but the findings have not yet been released [39]. 
 
Recombinant vaccines produced in plants 
In recent years, transgenic plants have been utilized as an alternative expression 
system to produce larger amounts of foreign proteins for use as edible vaccines 
[40, 41]. Several studies have already demonstrated that genetically engineered 
plants can serve as viable platforms for vaccine production and delivery, as well 
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as eliciting appropriate immunological responses in mice and humans immunized 
with these plant-based vaccines [42, 43, 44, 45].  
Oral vaccines are highly desirable due to their ease of administration and patient 
preference for non-injectable vaccinations.  Another advantage is that oral 
vaccines may stimulate production of mucosal antibodies more effectively than 
injectable vaccines [46,47]. Furthermore, edible oral vaccines are also expected 
to alleviate vaccine storage and refrigeration problems and associated costs that 
are commonly encountered .in recombinant vaccines produced by bacterial 
fermentation, thus rendering the former more available in developing countries.  
In addition, these plant-based vaccines will eliminate any contamination with 
mammalian viruses, prions, or other unknown agents that can be transmitted in 
cultured mammalian cells when used for subunit vaccine production [48, 49].  
It is important also to point out that if recombinant proteins are even produced in 
plastids of plant cells, via biolistic gene delivery technologies, they will also 
alleviate biosafety concerns due to undesired risk of gene flow via pollen spread 
as plastids in most plant species undergo uniparental maternal inheritance [50, 
51]. There is a consensus that transplastomic plants, genetically modified-plants 
in which gene of interest is inserted into chloroplast DNA, may be grown under 
field conditions without the risk of undesirable gene flow via pollen spread.  Yet 
another advantage of chloroplast-based recombinant protein expression is the 
possibility of accomplishing simultaneous expression of a number of genes in 
operon-like arrangements, thus allowing for design of multicomponent vaccines, 
carrying different antigens, and/or including adjuvant proteins [52]. 
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There are few reports of production of malaria-antigens in plants. The initial 
report of the successful expression of MSP1 in transgenic plants was published 
in 2002 [34]. Tobacco leaves were transformed by Agrobacterium tumefaciens 
carrying the MPS1 gene, and kanamycin resistant plants were regenerated; 
however, no immunogenicity or protection data have been reported.  This first 
malaria antigen expressed in plants by stable transformation, at very low levels of 
expression, is the 19-kDa C-terminal fragment of P. falciparum MSP1 (PfMSP119) 
[34]. This PfMSP119 has two cysteine rich epidermal growth factor (EGF)-like 
domain corresponding to a highly conserved region of MSP-1.  Several studies 
have highlighted the role of a full MSP1 as well as MSP119 in providing protection 
against malarial infections.  As MSP119 itself provides protection in mice [53] and 
monkeys [54], Therefore, it has been considered as a leading vaccine candidate 
against blood stages of malaria. 
 
Davoodi-Seromi et al. [55] have reported on expression of the cholera toxin-B 
subunit (CTB) of Vibrio cholerae fused to malarial vaccine antigens AMA1 and 
MSP1 in lettuce and tobacco chloroplasts.  It is reported that recombinant 
proteins of AMA 1 and MSP1 accumulated up to 13.17% and 10.11% in tobacco 
and up to 7.3% and 6.1% total soluble protein in lettuce, respectively. This 
candidate subunit vaccine has elicited antibodies in mice that inhibited parasite 
invasion of human RBCs in vitro, and has provided protection against cholera 
toxin challenge.  There is also a report of the production of transgenic plants 
expressing the immunoreactive PyMSP4/5. The tobacco-derived PyMSP4/5 
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protein is reported to induce antigen-specific antibodies in mice, and this 
recombinant protein reacts with a number of antisera that recognize the native 
protein in parasites. However, the antibody levels produced are not high enough 
to protect immunized test mice against a lethal challenge with Plasmodium yoelii 
[56]. 
Immunization with purified protein antigens usually results in the production of a 
modest antibody responses with either little or no T cell responses.  Furthermore, 
multiple immunizations may be required to elicit sufficient antibody responses 
[57].  Thus, incorporation of adjuvant components may contribute to enhanced 
and desirable immune responses against a tested pathogen or parasite.  
Adjuvants 
Adjuvants are molecules or macromolecular structures that are used to induce 
more effective and long-lasting protective immune responses to antigens. The 
oldest and widely recognized mechanism of action of adjuvants is the generation 
of a depot that traps antigens at the site of injection, which permits slow release 
of an antigen, thus maintaining continuous stimulation of the immune system for 
the production of high titers of antibodies. These types of adjuvants increase 
antigen persistence at the site of infection and increase recruitment and 
activation of antigen presenting cells (APCs).  Also, some adjuvants are capable 
of directing antigen presentation by the major histocompatibility complexes 
(MHCs) [58,59,60]  
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Other adjuvants, such as ligands for pattern recognition receptors (PRR), act via 
inducing the innate immunity by targeting the APCs and influencing the adaptive 
immune response. Members of the PRR families are potential targets for 
adjuvants. These comprise Toll-like receptors (TLRs), NOD-like receptors 
(NLRs), RIG-I-like receptors (RLRs), and C-type lectin receptors (CLRs). These 
signal through pathways that involve distinct adaptor molecules, leading to the 
activation of different transcription factors, and inducing production of cytokines 
and chemokines, which are key players in priming, expansion, and polarization of 
the immune responses. Activation of some members of the NLR family, such as 
NLRP3 and NLRC4, triggers the formation of an inflammasome that is 
associated in the stimulation of the pro-inflammatory cytokines IL-1β [2] and IL-
18 [61,62,63].  
 
Rationale and Significance 
Malaria is the most prevalent tropical disease caused by protozoan parasites. 
Half of world's population is at risk of malaria, and more than 200 million of new 
cases are reported annually. Currently, there are no approved vaccines available 
for control of the disease, and treatments suffer from several limitations. 
Therefore, a novel approach towards developing an anti-malaria vaccine is 
needed. 
Although several single proteins have shown some promise as subunit vaccines 
against sexual blood stages in experimental systems, it is clear that 
multicomponent vaccines are required to generate a combination of antigens 
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which is an essential requirement for developing an efficacious malaria vaccine.  
However, the cost of the development and deployment of such a vaccine using 
current practices is very high. 
Overall Goal 
The overall goal of this project is to develop a plant-based subunit vaccine 
against malaria.  This subunit vaccine will rely on the use of several epitopes of 
Plasmodium falciparum, expressed in transplastomic plants, such as tobacco. 
This will serve as a model for a low-cost recombinant vaccine production system 
against malaria. 
Specific objectives  
1. Design and optimize a synthetic gene(s) for enhanced transcription and 
translation in plants, encoding an antigenic peptide for plastid transformation. 
2. Transfer of the gene construct using a biolistic particle delivery system and 
regeneration of transplastomic plant lines. 
3.  Analysis and characterization of putative transplastomic tobacco lines and 
evaluation of expression levels of the heterologous proteins. 
4. Immunogenicity assessment of the selected transplastomic tobacco line in 
vitro (human serum from malaria infected patients) and in vivo (BALC/c 
mice).  
5. Mice Immunogenicity assessment of the proposed malaria antigens in 
combination of different vaccine adjuvants via oral and subcutaneous 
administration 
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CHAPTER 2 
An Ama1/ Msp119 Adjuvanted Malaria Transplastomic Plant-Based Vaccine 
Induces Immune Responses In Test Animals 
ABSTRACT 
Malaria is the most prevalent tropical human disease reported worldwide.  This 
disease is caused by protozoan parasites. Half of the world's population is at risk 
of malaria, and more than 200 million new cases are reported annually. 
Currently, there are no licensed vaccines available for use, but only prevention 
treatments, and often these suffer from limitations. Therefore, there is an urgent 
need for developing an effective and reliable anti-malaria vaccine. Plant-based 
vaccines serve as novel platforms for developing safe, reliable, and affordable 
treatments. In this study, a Malchloroplast candidate vaccine is designed, 
composed of segments of AMA-1 and MSP-1 proteins along with the GK1 
peptide form Teania solium as adjuvant, and this has been expressed in tobacco 
chloroplasts. Transplastomic tobacco lines have been generated using biolistic 
transformation, and these are confirmed to carry the synthetic gene construct. 
The synthetic GK1 peptide is confirmed to be expressed using RT-PCR and 
Western blots.  Furthermore, the GK1 peptide is detected by HPLC at levels of 
up to 6 µg g-1 dry weight of tobacco leaf tissue. The plant-derived Malchloroplast 
candidate vaccine has been subsequently tested in BALB/c female mice 
following subcutaneous administration, and found to elicit specific humoral 
responses.  Furthermore, components of this candidate vaccine have been 
recognized by antibodies in Plasmodium falciparum Malaria patients, and has 
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elicited specific antibodies in immunized BALB/c mice. Thus, this study has 
provided a ‘proof of concept’ for a promising plant-based candidate vaccine 
against malaria. 
INTRODUCTION 
Malaria is a potentially deadly tropical disease, with an estimated 500 million 
reported infections reported per year, resulting in approximately - ½ million 
deaths annually, of mostly children under 5 years of age [1]. Malaria infection is 
caused by any one of four species of protozoan parasites, belonging to the 
Plasmodium genus. Although there are dozens of species of malaria parasites, 
those that infect humans are limited to P. falciparum, P. vivax, P. ovale, and P. 
malariae.  Among these, P. falciparium and P. vivax are the most common, and 
in particular P. falciparum is the deadliest [2]. Malaria along with malnutrition can 
contribute to serious consequences, wherein malnourished children (mostly 
under 5 years of age) are less likely to fight-off against the disease, and thereby 
leading to higher likelihood of sustaining mortality [3,4]. 
Vaccines are proposed to serve as promising tools for malaria prevention and 
control. An idyllic malaria vaccine should afford protection against a pre-
erythrocytic infective stage and a blood stage of the parasite, as well as serve as 
a transmission-blocking tool. Progress towards developing an efficacious vaccine 
has not yet been accomplished.  This is due to the high level of polymorphism of 
prospective target antigens, as well as incapability of most tested candidate 
vaccines in eliciting long-lasting immunological memory in the host [5].  Recently, 
results from a Phase III vaccine trial targeting a circumsporozoite protein 
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expressed during the pre-erythrocytic stage, RTS,S/AS01, suggest that its 
implementation would be beneficial for disease control when used in combination 
with bed nets in areas of high disease transmission yielded promising results and 
raising hopes for the first licensed vaccine against malaria [6,7].  
A blood stage apical membrane antigen 1 (AMA1) vaccine, which is also 
expressed during sporozoite and hepatic stages, has demonstrated protective 
efficacy in both rodents and simian models, thus suggesting that AMA1 is an 
important target of naturally acquired protective antibodies in humans [8-10]. The 
capacity of AMA1 to elicit protective immunity in humans has been demonstrated 
in a phase II b vaccine trial in children of 1 to 6 years in age - in Mali [11].   Some 
reports have highlighted the role of a full-length Merozoite surface protein 1 
(MSP1) as well as the C-terminal 19 kDa region of MSP1 (MSP119) in providing 
protection against malaria infection, as MSP119 has been reported to provide 
protection in both mice [12] and monkeys [13].  Thus, MSP119 is deemed as a 
leading vaccine candidate against blood stages of malaria.  Currently, there is no 
licensed vaccine for malaria prevention. A phase I clinical trial for a 
multicomponent blood stage antigens MSP1 and AMA1, along with alhydrogel 
used as an adjuvant, on adults in the United States and in Mali adults took place, 
results are not yet released [14]. 
Although several single proteins have demonstrated some promise as candidate 
subunit candidate vaccines against sexual blood stages of malaria in 
experimental systems, there is a need for developing multicomponent vaccines. 
Using a combination of antigens seems to be an essential requirement for 
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developing an efficacious malaria vaccine, but costs associated with 
development of such a vaccine are very high. Therefore, plant based-vaccines 
serve as viable platforms for producing large amounts of antigenic proteins at low 
cost [15,16], as well as eliciting appropriate immunological responses [17,18], 
and easily administered to patients [19,20]. Several plant-based vaccines are 
currently under development against diverse groups of pathogens and diseases, 
and some are currently in clinical trials [21]. 
 
Among various genetic engineering approaches for antigen expression in plant 
cells, transplastomic technologies, i.e., foreign gene incorporation and 
expression in plastids, contribute to attaining high protein yields in plants [22].  
Furthermore, this has allowed for the development of oral immunotherapies of 
freeze-dried plant material encapsulated in gelatin pills [23]. As low 
immunogenicity is often observed in subunit vaccines, adjuvants play a key role 
in vaccine efficacy. The GK1 peptide from Taenia solium is an 18 amino acid 
peptide with an adjuvant properties, and has proven to be effective at enhancing 
vaccine performance, but without producing undesirable secondary effects [24, 
25].      
The aim of this study was to develop a plant-based subunit vaccine against 
malaria, comprised of AMA1 and MSP119 epitopes of P. falciparum and 
expressed in tobacco chloroplasts, to serve as a model for a low-cost 
recombinant malaria vaccine production system. 
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MATERIALS AND METHODS 
Gene and vector construction 
A synthetic polycistronic arrangement called Malchloroplast was design to 
achieve the expression of the two malaria antigens AMA1 and MSP119 along with 
a GK1 peptide, as an adjuvant. Open reading frames (ORF) were optimized as 
per codon bias for tobacco gene expression, and synthesized by Genescript 
(Piscataway, NJ).  Both mRNA processing and destabilizing motifs were 
excluded from this synthetic gene. The 766-bp sequence includes ribosome 
binding site upstream each ORF and with XbaI and XhoI restriction sites at the 5’ 
and 3’ ends, respectively.  
For plastid transformation, the plasmid pBic vector was used as previously 
described by Rosales-Mendoza et al. [26]. This vector has been designed for 
integration of foreign genes into a MunI restriction site, and in between trnN-GUU 
and trnR-ACG in the inverted repeat region of the chloroplast genome [27]. The 
Malchloroplast coding sequence was subcloned into the pBic vector, and 
digested with XbaI and XhoI restriction enzymes.  The pBic vector expresses the 
Malchloroplast and aadA genes as bicistrons under the control of the plastid 16S-
rRN-promoter (Prrn). The schematic diagram of the resulting plasmid, pBic-
MalChloro, is presented in Fig. 1. All cloning and analysis procedures were 
performed following standard protocols [28]. Plasmid DNA for plastid 
transformation was prepared using the Qiagen Plasmid Midi Kit (Qiagen, 
Valencia, CA).  
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Plastid Transformation 
Plant transformation was conducted according to the protocol described by 
Daniell et al. [29]. Briefly, tobacco petite havana seedlings were grown 
aseptically on a Murashige and Skoog (MS) medium for a period of 3 to 5 weeks. 
Full-expanded leaves were collected and used for bombardment using the PDS-
1000/He (Bio-Rad, CA) biolistic gene gun.  Gold particles (0.6 µm in diameter) 
were coated with the pBic vector carrying the target genes and bombarded onto 
leaf tissues as previously described [29]. Following bombardment, leaves were 
incubated with RMOP medium for 48 h in the dark. Then, leaves were cut into 
small sections (~5 mm X 5 mm), and cultured with the abaxial side in contact with 
the RMOP medium containing 500 mg/L spectinomycin.  Following 8 weeks of 
incubation, leaves from putative transplastomic shoots were cut into small 
sections, and cultured onto a fresh selection medium for the next round of 
selection. After three selection rounds, spectinomycin-resistant shoots were 
continuously cultured on an MS medium containing 500 mg/L spectinomycin for 
inducing roots. Whole plants were transferred to soil, acclimatized, and grown in 
the greenhouse until maturity. After flowering, seeds from 12 plants were 
collected, and germinated on MS medium containing spectinomycin for analysis. 
PCR and RT-PCR  
Total DNA from 12 T0 plants was extracted from putative transplastomic and non-
transformed tobacco leaves using the DNAeasy™ Plant Mini Kit (Qiagen, 
Valencia, CA). For PCR analysis, a 25 µl reaction mixture containing 100 ng 
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DNA, 1.5 mM magnesium chloride, 2.5 U Taq DNA polymerase, 1 mM dNTPs, 
and 1 µM of each of forward and reverse primers was used. The forward primer 
ChloroF (5’ TCTAGAAGGGAGGGACAT) and reverse primer ChloroR (5’ 
CTCGAGCGTCAGTTAGAAGAA) were used to amplify AMA1 and MSP119 
genes.   
To assess for homoplasty, the following primers were used: 5’ -
AAGAATGGGTGAGGGTATTCTGCC- TAAATA (sense) and 5’ -
GCATCTAAGTAGTAAGCCCACCCCAAGATG (anti-sense). The PCR protocol 
included an initial denaturation step at 94°C for 5 min followed by 35 cycles of 
denaturation, annealing, and extension steps of 30 s at 94°C, 30 s at 55°C, and 
60 s at 72°C (240 s for homoplasty assay), respectively, and a final extension at 
72°C for 5 min. PCR products were analyzed by electrophoresis on 1% agarose 
gels. PCR-positive lines were transferred to the greenhouse for plant growth and 
seed production. T1 seeds were collected and germinated on an MS medium 
containing 500 mg/L of spectinomycin. 
To assess whether the introduced sMalchloroplast polycistron was expressed, 
Total RNA was extracted from leaves of transplastomic and wild-type tobacco 
plants using a Trizol reagent (Life technologies, Carlsbad, CA) according to the 
supplier’s instructions. One micrograms of total RNA was used to generate cDNA 
with Superscript III First-Strand System (Life technologies, Carlsbad, CA). A 
region of the b-actin mRNA was amplified using primers 5’ -
AACTGGGATGACATGGAGAA and 5’-ATCACACTTCATGATGGAGTTGTAfor 
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loading control. PCR analysis was performed using the primers and amplification 
protocol described above in order to detect a 766-bp amplicon derived from 
Malchloroplast transcripts.  
Protein analysis 
Expression of both AMA-1 and GK1 peptides in transplastomic plants lines 
MC9T1S9, MC9T1S13, MC9T1S14 and MC9T1S16 was assessed using a 
Western blot assay. Protein extracts were obtained using 20 mg of freeze-dried 
tissues, which were homogenized in 300 µl of extraction buffer (750 mM Tris-HCl 
pH 8.0, 15% sucrose wt/vol, 100 mM β-mercaptoethanol, 1 mM PMSF).  
Following centrifugation at 8000 rpm for 15 min, supernatants were recovered, 
and 50 µl samples were mixed with an equal volume of 2X reducing loading 
buffer (4% SDS, 20% Glycerol, 0.1 2M Tris pH 6.8, 5% β-Mercaptoethanol).  An 
Eschericia coli-produced poli-GK1 recombinant protein, comprised of six GK1 
tandem repeats in a single polypeptide, was used as a positive control. Samples 
were denatured by boiling for 5 min at 95°C, debris was eliminated by 
centrifugation at 16,000 g for 15 min at 4°C, and SDS-PAGE was performed in 
4–12% acrylamide gels under denaturing conditions. The gel was blotted onto 
BioTrace PVDF membranes (Pall Corporation, http://www.pall.com). After 
blocking with PBS-Tween 0.05% (100 mM NaCl, 10 mM Na2HPO4, and 3 mM 
KH2PO4; pH 7.2) plus 5% fat-free milk (Carnation, Nestle), blots were incubated 
overnight with either an anti-GK1 antiserum against the GK1 synthetic peptide at 
1:800 dilution, raised in mice, as previously described by Monreal-Escalante et 
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al. [30], a monoclonal antibody anti-AMA1 (at 1:250 dilution, Lifespan 
Biosciences, Seattle, WA), or a monoclonal anti-MSP1 antibody (1:500 dilution, 
Abcam, Cambridge, MA). Thereafter, blots were incubated at 1:2,000 dilutions 
with either goat anti-mouse horseradish peroxidase-conjugated antibody or anti-
rabbit horseradish peroxidase-conjugated antibody (Sigma, St. Louis, MO) for 2 h 
at room temperature to visualize binding of specific antibodies.  Antibody binding 
was detected with the Super Signal West Dura solution, following the 
manufacturer’s instructions (Thermo Scientific, Waltham, MA), and by means of 
an X-ray film, following standard procedures. 
Detection of Plant-Derived Antigens by ELISA 
About 20 mg of freeze-dried tissues from the 4 transplastomic lines were milled 
and resuspended in 100 µl of protein extraction buffer (750 mM Tris-HCl pH 8.0, 
15% sucrose wt/vol,1 mM PMSF). Samples were centrifuged at 14,000 rpm in a 
microcentrifuge for 10 min at 4°C. Assay plates were coated overnight at 4°C 
with protein extracts diluted in carbonate buffer (15 mM Na2CO3 and 35 mM 
NaHCO3; pH 9.6). Plates were washed with PBST and blocked with 5% fat-free 
dry milk for 1 h at room temperature. After washing with PBST, anti-GK1 
antiserum (1:800) or sera from two Plasmodium falciparum-positive patients was 
added and the plates were incubated overnight at 4°C. A horseradish 
peroxidase-conjugated goat anti-mouse IgG antibody (1:2000; Sigma, St. Louis, 
MO) was added and incubated for 2 h. After washing with PBST, a substrate 
solution composed of 0.3 mg/l 2-20- Azino-bis-3 etilbenztiasoline-6-sulphuric acid 
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(ABTS; Sigma, St. Louis, MO) and 0.1 M H2O2 was added. The optical density 
(OD) at 405 nm was recorded in a Multiskan Ascent (Thermo Scientific, 
Waltham, MA) microplate reader. 
GK1 quantification by HPLC 
Protein extracts were obtained by resuspending 20 mg of freeze-dried leaf tissue 
in 300 µl of extraction buffer (750 mM Tris-HCl pH 8.0, 15% sucrose wt/vol, 100 
mM β-mercaptoethanol, 1 mM PMSF), and the supernatants were mixed with 
100 µl of 0.1%TFA/water with Photometric grade trifluoroacetic acid (TFA, 
Sigma-Aldrich).  Extracts were analyzed in an Agilent 1260 Infinity Binary LC 
Chromatography RP-HPLC System (Agilent Technologies, INC. Palo Alto, CA), 
and data were analyzed with ChemStation software.  
Protein extract samples (100µL) from either transgenic or WT plants were 
injected into the equipment using a ZORBAX Eclipse XDB C18 column (4.6 × 
150 mm, 5 µm) (Agilent Technology, Palo Alto, CA) equilibrated with 0.1%TFA in 
water.  Separation was carried out at 30°C using a linear gradient of aqueous 
acetonitrile containing 0.1% TFA at a flow rate of 1 mL/min. The acetonitrile 
concentration was increased from 0% to 50% over 75 min and held constant 
thereafter. Column effluent was monitored using UV absorption, measured at 217 
nm, to identify signal peptides in extracts of plant tissues. Major peaks from the 
HPLC chromatogram were identified individually. The concentrations of peptide 
in the extract plants were identified using a GK1 synthetic peptide (1.8 mg/mL) as 
a standard. 
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Mice immunization  
Immunogenicity of tobacco-derived sMalchloroplast candidate vaccine was 
evaluated in female BALB/c mice (8 weeks of age) that were housed in filter-
topped cages, and cared for according with federal regulations for animal 
experiments (NOM-062- ZOO-1999, Ministry of Agriculture, Mexico). The 
immunization protocol was approved by the Institutional Animal Care and Use 
Committee (IACUC).  
Mice were randomly divided into three different groups (n = 4), each group 
receiving the following treatments: 5 mg of freeze-dried tobacco leaf powder from 
transgenic line MC9S16, 5 mg of freeze-dried tobacco leaf powder from wild-type 
plants, and the vehicle alone (PBS). Four weekly doses were subcutaneously 
administered to each group on days 1, 8, 15, and 22. At day 43 mice were 
boosted with a formulation comprised of four synthetic peptides along with the 
complete Freund´s adjuvant (MSP1-1: QGMLNISQHQCVKKQCPQNS; MSP1-2: 
DSGSNGKKITCECTKPDSYPLFDGIFCSSSN; 
AMA1:SKRIKLNDNDDEGNKKIIAPRIFIS; and GK1: 
GYYYPSDPNTFFYAPPYSA).  Mice were bled on days 14, 21, 28, and 42; and 
then sacrificed on day 50. Serum samples were collected from blood extracted 
following cardiac punctures.  
ELISA assays  
The antibody content was determined by enzyme linked immunosorbent assay 
(ELISA).  For each reagent/sample used in this assay, 100 µl were used, unless 
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noted otherwise.  Plates were coated with 1 µg MSP1-1, AMA1 and GK1 
peptides per well, diluted in a carbonate/bicarbonate buffer, incubated overnight 
at 4°C, and blocked with 5% fat-free milk dissolved in PBST. Serum samples 
diluted (dilution 1:20) in PBST were then added. Triplicates from each sample 
were incubated overnight at 4°C. A horseradish peroxidase conjugated goat anti-
mouse anti-immunoglobulin G (IgG) antibody (Pierce, Rockford, IL) was then 
added to each well, and plates were incubated for 2 h at room temperature. 
Plates were washed, and the ABTS substrate solution along with 0.1 M H2O2 
were added. The OD at 405 nm was recorded with a Multiskan Ascent (Thermo 
Scientific, Waltham, MA) microplate reader.  
RESULTS 
Design of polycistron and construction of expression vector 
The synthetic polycistron is comprised of coding regions for the two malaria 
antigens (AMA1 and MSP119) along with an adjuvant peptide (GK1). The 
synthetic polycistron was also optimized for per codon bias for tobacco genes 
and synthesized by Genescript (Piscataway, NJ), with both mRNA processing 
and destabilizing motifs avoided. The Malchloroplast gene was inserted into the 
plastid expression cassette of the pBic vector as confirmed by both restriction 
profiles analysis and sequencing.  
The design of pBic vector is to integrate foreign genes into the MunI restriction 
site, and in trnN-GUU and trnR-AGG inverted repeat region of the chloroplast 
genome [27]. The pBic vector expresses the MalChloroplast and aadA genes as 
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bicistrons under the control of the plastid 16S-rRN-promoter (Prrn) (Fig. 2.1). The 
ligation reaction was carried out using standard protocols, and then used to 
transform chemically competent cells of E. coli TOP10 (Invitrogen). After 
obtaining individual clones of E. coli cells resistant to ampicillin, a colony PCR 
was carried out to identify clones carrying the expected construct (Fig. 2.2). 
Positive clones were used to isolate plasmid DNA and confirmed the presence of 
inserts by restriction profiles and by sequencing. Clones with the correct insert 
sequence were used for plant transformation using the biolistic delivery system.  
 
Analysis of plastid-transformed tobacco plants  
The pBic-Malchloroplast construct was introduced into tobacco leaf tissues by 
microprojectile bombardment, and callus was observed on explants after 8 
weeks of incubation on the selection medium.  Several independent 
transformants were rescued and regenerated under the spectinomycin containing 
selection medium. A total of 11 kanamycin-resistant plantlets were successfully 
transferred to soil, acclimatized, and grown to maturity in the greenhouse (Fig. 
2.3).  
The presence of the transgene in T0 transformed plants was determined by PCR 
screening using primers specific (MCF and MCR) for the Malchloroplast 
transgene. A 0.766 kb PCR-specific band was amplified in five putative 
transplastomic plants and was absent in wild-type tobacco plants (Fig. 2.4).  In 
addition, a 0.438 kb PCR-specific band for the aadA region was amplified from 
these five putative transplastomic plants (Fig. 2.5).  Seeds from T0 PCR-positive 
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plants were placed on an MS medium containing 500 mg/L of spectinomycin.  
One of the five putative transplastomic lines germinated, and was designated as 
Plant 9. Plants from this line were transferred to pots containing soil mix and 
grown in the greenhouse until maturity (Fig. 2.6). To assess the homoplastic 
state in candidate plants, a PCR analysis was performed using primers landing 
on adjacent regions of the insertion site of the chloroplast genome. All four 
analyzed plants from Plant 9 yielded the 2.6 kb product, expected for insertion 
events, while the WT line yielded a 1.8 kb.  This is the expected pattern observed 
for homoplastic lines. 
The sMalchloroplast transgene is actively transcribed in transplastomic 
plants  
To determine the transcriptional activity of the heterologous expression cassette, 
qRT-PCR analysis was conducted for the Malchloroplast polycistron and actin-
mRNA as an internal control. sMalchloroplast transcripts were not detected in 
wild-type leaf tissues; whereas, positive amplification was observed in 4 analyzed 
transplastomic plants: MC9T1S9, MC9T1S13, MC9T1S16 (Ct values ranging 
from 22.93 to 16.27), indicating that the synthetic polycistron was transcribed. 
The delta Ct using the actin amplification signal was in the range of 678.25 to 
44.9, wherein the MC9T1S16 showed the highest sMalchloroplast mRNA levels. 
sMalchloroplast vaccine components are correctly expressed in 
chloroplast and retain their antigenic activities  
To analyze expression of malaria antigens in leaf tissues, we first conducted an 
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HPLC analysis to quantify GK1 content. Retention time for the GK1 synthetic 
peptide was 32.6 min. Total soluble protein fractions from transplastomic lines 
revealed the presence of a peak of the expected retention time.  This is in 
contrast with patterns observed for the WT line, wherein a peak at 32.6 min 
showed almost no detectable signal. Based on this analysis, estimated GK1 
levels reached values of up to 6 µg/g dried-tissue (line S9; Table 2.1; Fig. 2.7).    
In addition, the GK1 adjuvant was detected by specific antibodies against GK1 
using Western blotting and ELISA assays for total soluble protein (TSP) extracts 
from four T1 transplastomic lines, non-transformed plants, and positive controls. 
T1 transplastomic plants showed positive activities at molecular weight band of ~ 
14 kDa, whereas the positive control (poly-GK1 protein) showed reactivity at ~ 26 
kDa (Figure 2.8 a and b, respectively). Also, the presence and antigenicity of 
AMA1 proteins was assessed by Western blot analysis using an anti-AMA1 
antibody for labeling, wherein tested lines showed positive reactivities to this 
malaria antigen at a molecular weight of 14 kDa, as expected (Fig. 2.8c). Similar 
positive results were obtained when sera from Plasmodium falciparum malaria-
infected patients were used for labeling on an ELISA assay, indicating that 
malaria antigenic determinants were present in the plant-derived sMalchloroplast 
candidate vaccine (Fig. 2.9). 
Immunogenicity of tobacco-derived Malchloroplast 
Immunogenicity of the plant-derived Malchloroplast was assessed using a four 
weekly immunization scheme of test mice. Following antibody content 
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measurement by ELISA, mice immunized with tobacco tissue from line S16 
showed significant reactivity against AMA1, MSP1, and GK1 peptides; whereas, 
a significant lower signal was observed for the group immunized with WT 
tobacco (Fig. 2.10 a, b and c, respectively). These findings demonstrated 
presence of antibodies recognizing the specific malaria epitopes, suggesting that 
the tobacco-derived Malchloroplast has the appropriate immunogenic potential. 
DISCUSSION  
The first malaria antigen expressed in plants by stable transformation, at a low 
expression level, was that of the 19-kDa C-terminal fragment of P. falciparum 
MSP119 (PfMSP119 ) [31]. This PfMSP119 has two cysteine rich epidermal growth 
factor (EGF)-like domains, corresponding to a highly conserved region of MSP-1; 
however, there are no immunogenicity or protection data available. Several 
studies have highlighted the role of full MSP1 as well as MSP119 in providing 
protection against malarial infection. As MSP119 alone provides protection in 
mice [32] and monkeys [33], it is being considered as a leading vaccine 
candidate against blood stages of malaria.  
In 2008, Wang et al. [34] reported on the production of transgenic plants 
expressing an immunoreactive PyMSP4/5.  Tobacco lines expressing the 
PyMSP4/5 protein were capable of inducing antigen-specific antibodies in mice.  
Furthermore, this protein reacted with several antisera that recognize the native 
protein in parasites. However, antibody levels produced were not high enough to 
protect immunized mice against a lethal challenge with Plasmodium yoelii. Given 
the improbability that a vaccine directed against a single antigen will be 
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completely protective, the preferred option is to combine several antigens of 
different stages of infection of the parasite in a multi-component multi-stage 
vaccine. AMA1 and MSP1 are promising malaria vaccine antigens as they are 
reported to be essential for merozoite invasion of erythrocytes. While MSP1 is 
found along the merozoite surface, AMA1 is localized in apical organelles, and it 
is discharged onto the merozoite surface during or just prior to invasion of 
erythrocytes [35]. Data in rodent and non-human primate model systems have 
provided supporting evidence that both of these molecules produced as 
recombinant proteins can elicit protective responses to parasite infection 
[36,37,38]. 
In this study, a polycistronic arrangement was constructed and transferred into 
the chloroplast genome of tobacco for expression of AMA1 and MSP1 malaria 
antigens along with the GK1 peptide, used as an adjuvant. Following particle 
bombardment, 11 independent transformants were rescued on a selection 
medium, from which six plants were positive for presence of transgene following 
PCR analysis. The five negative lines showed resistance to spectinomycin, but 
they lacked the transgene, thus suggesting these are likely to be escapes during 
selection.  
Homoplasty of putative transplastomic plants was confirmed by PCR due to 
presence of a 2.6 kb amplicons, corresponding to presence of the foreign DNA, 
in these lines, and thus confirming the homoplastic state of these lines.   
Four T1 PCR-positive lines (MC9T1S9, MC9T1S13, MC9T1S14 and MC9T1S16) 
were selected for protein characterization, showing immunoreactivity against 
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anti-AMA1 and anti-GK1 specific antibodies, and providing evidence for 
expression of these recombinant proteins. Immunoreactivity of the GK1 revealed 
retention of the antigenic determinants in the plant-made GK1. This adjuvant has 
been previously expressed in plant cells retaining immunogenic activities [30].  
Moreover, it can be noted that sera from patients known to be positive for Malaria 
from Plasmodium showed immunoreactivity for four transplastomic lines. 
Therefore, these findings indicate that plant chloroplasts can serve as a low-cost 
and efficient platform for production of multiepitopic malaria proteins and 
retaining their antigenic determinants.  
Test mice immunized with plant extracts from line MC9T1S16 developed 
antibody responses against AMA1, MSP1, and GK1.  Moreover, different 
responses were observed between mice immunized with the MC9T1S16 line 
versus those treated with non-transformed plant tissues, following administration 
of the final dose. Furthermore, no significant differences were observed following 
the peptide boost administration.    
All the above findings suggest that the recombinant tobacco-derived 
Malchloroplast induced systemic antibody response.  In order to determine 
whether an effective protective immune was induced, a parasite lethal challenge 
study should be conducted to assess test animal response and survival. 
In conclusion, we have successfully expressed the multi-epitope Malchloroplast 
polypeptide in transplastomic tobacco plants, with the potential to serve as a 
model of an immunogenic and low cost vaccine formulation. 
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FIGURES 
 
 
 
 
 
 
 
Figure 2.1. Plasmid pBic containing Malchloroplast coding-sequence under the 
control of the plastid 16S-rRN-promoter (Prrn).  
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Figure 2.2. Gel electrophoresis of PCR screening of E. coli positive colonies 
carrying the Malchloroplast construction. Malchloroplast transgene with expected 
size of 766 bp. 
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Figure 2.3. Putative transplastomic T0 plants carrying the Malchloroplast 
construction. a. T0 seeds germinating on a medium containing 500mg/L 
spectinomycin. b. T0 mature plant transferred to soil and grown in green house 
exhibiting normal phenotype. 
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Figure 2.4. Gel electrophoresis of PCR screening of the T0. Plasmid DNA is 
from pBic-Malchloroplast and served as the positive control. Wild-type tobacco 
served as the negative control. Malchloroplast transgene with expected size of 
766 bp.  
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Figure 2.5. Gel electrophoresis of PCR screening of the T0. Plasmid DNA is 
from pBic-Malchloroplast and served as the positive control. Wild-type tobacco 
served as the negative control. aadA selectable marker with expected size of 
about 438 bp. 
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Figure 2.6. Putative transplastomic tobacco T1 plants carrying the 
Malchloroplast construction. a. T1 seeds germinating on a medium containing 
500mg/L spectinomycin. b and c.T1 mature plants transferred to soil and grown 
in green house exhibiting normal phenotype. 
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Figure 2.7.  RP-HPLC elution profile illustrating the purification of GK 1 synthetic peptide (a). Analytical 
profile (1.8 mg) of peptide from liquid phase water/TFA 0.1%. Column: Zorbax 300 RP-C18, 25 cm × 4.6 mm 
id, 5-µm particle size, 30 nm pore size. Conditions, linear gradient from 0–50% acetonitrile with 0.1%TFA 
over 75 min, flow rate of 1 mL/min, 30°C. Elution profiles of the transgenic lines samples, (b) MC9T1S9, (c) 
MC9T1S13, (d) MC9T1S14, (e) MC9T1S16 and (f) WT. 
a b 
d c 
e f 
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Figure 2.8a. Immunodetection of GK1 adjuvant in tobacco protein 
extracts. Western blot was conducted using a rabbit polyclonal anti-GK1 
antibody. Samples, pure recombinant tandem repeated GK1 peptide as 
positive control; protein extracts from lines MC9T1S9, MC9T1S13, 
MC9T1S14 and MC9T1S16 and wild-type tobacco plant. 
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Figure 2.8b. Antigenic activity of tobacco protein extracts. Wild type or 
MC9T1S9, MC9T1S13, MC9T1S14 and MC9T1S16 lines were analyzed 
by ELISA using polyclonal rabbit antibody against GK1. Asterisks denote 
significantly higher values with respect to Wild-type protein extract. 
(P<0.05). 
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Figure 2.8c. Immunodetection of AMA1 antigen in tobacco protein 
extracts. Western blot was conducted using a monoclonal anti-AMA1 
antibody. Protein extracts of MC9T1S9. MC9T1S13, MC9T1S14 and 
MC9T1S16 and WT were used. 
 
 
 
 
! 57!
 
 
 
 
 
 
 
Figure 2.9. ELISA analysis showing reactivity of sera from Plasmodium 
falciparum malaria infected patients with the tobacco-derived Malchloroplast 
produced in the MC9T1S9, MC9T1S13, MC9T1S14 and MC9T1S16 lines.  
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Figure 2.10a. Levels of antibodies induced by the transgenic tobacco 
MC9T1S16 line in immunized mice, specific for the MSP1 antigen (light green 
bar). OD values from mice sera immunized with wild-type tobacco are shown in 
dark green bars. Asterisk denote significantly higher values with respect to WT-
treated group (P<0.05). 
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Figure 2.10b. Levels of antibodies induced by the transgenic tobacco 
MC9T1S16 line in immunized mice, specific for the AMA1 antigen (light green 
bar). OD values from mice sera immunized with wild-type tobacco are shown in 
dark green bars. Asterisk denotes significantly higher values with respect to WT-
treated group (P<0.05). 
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Figure 2.10c. Levels of antibodies induced by the transgenic tobacco 
MC9T1S16 line in immunized mice, specific for the GK1 adjuvant (light green 
bar). OD values from mice sera immunized with wild-type tobacco are shown in 
dark green bars. Asterisk denote significantly higher values with respect to WT-
treated group 
(P<0.05). 
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TABLES 
Table 2.1. Characterization of transgenic lines expressing GK1 peptide by RP-
HPLC. 
 
Sample 
Standard 
(GK1) 
S9 S13 S14 S16 WT 
Area (mAU) 24028.3 1028.9 838.3 503.7 754.64 120.9 
Time (min) 32.64 32.37 32.32 32.29 32.27 32.39 
µg/g dried-
tissue 
- 6.0 5.1 3.7 4.8 Undetermined 
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CHAPTER 3 
Evaluation Of Mucosal Adjuvants With An Oral Peptide Based Malaria 
Vaccine For Their Ability To Evoke Humoral Responses In Mouse 
ABSTRACT 
Designing an effective vaccine for malaria disease prevention is of special 
importance as 3.2 billion individuals are annually at risk of contracting the 
disease. An ideal protective malaria vaccine should be comprised of different 
antigens that generate appropriate cell-mediated antibody responses of the 
parasite presentation.  In this study, a peptide-based vaccine (Mvac) targeting 
the MSP1 and AMA1 antigens was evaluated in combination with different 
adjuvants in an oral immunization scheme applied to BALB/c mice. Test 
adjuvants were plant DNA, pectin, and the GK1 peptide from T. solium. Neither 
plant DNA nor pectin enhanced the humoral response induced against the Mvac 
components. GK1 peptide exerted adjuvant effects in terms of the systemic IgG 
responses induced against the AMA1 peptide, whereas pectin enhanced the IgA 
intestinal secretion against both MSP1 and AMA1 antigens. The potential of the 
Mvac vaccine as well as the implications of the GK1 as adjuvant in the 
development of oral anti-malaria vaccines are discussed.  
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INTRODUCTION 
 
Vaccines are known as the most cost-effective health control measures against 
disease, and for protecting populations against myriad pathogenic organisms and 
agents [1].  Effective and viable vaccines must be capable of stimulate immune 
responses that will confer protection against a specific pathogen. Additionally, 
they must be safe and capable of producing long-lived immunological memory, in 
many cases this requires both humoral and cell mediated immunity.  
Furthermore, vaccines should be affordable, particularly if they are to be 
administered to large populations, and especially for those in developing 
countries. Peptide vaccines are composed of one or more protein antigens that, 
when administered, elicit protective immunity against the target pathogen. These 
forms of vaccines, although promising, have several disadvantages. Firstly, a 
particular candidate peptide may not bind to Major Histocompatibility Complex 
(MHC) molecules as humans are highly polymorphic for the MHC region.  
Secondly, if there is a direct exchange of short peptides of MHC molecules but 
without physiological antigen processing and peptides are loaded directly onto 
MHC molecules other that dendritic cells (DCs), this can induce tolerance of T 
cells rather than stimulating immunity. Thirdly, if synthetic vaccine peptides are 
efficiently processed for presentation by MHC class II molecules but these do not 
enter the MHC class I processing pathway, this failure of MHC class I 
presentation would severely restrict activation of cytotoxic CD8 T cells [1,2,3].  
Yet another drawback is that peptide-vaccines often do not activate the innate 
immune system as well as a natural infection would. Thus, these groups of 
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vaccines will require additional components to mimic how infections activate 
innate immunity, which in turn would induce DCs to become stimulatory T cells 
[3]. 
Adjuvants are components normally used in vaccines to enhance immune 
responses. Generally, they are classified into two groups [4].  One group is that 
of vehicles, such as mineral salts, emulsions, liposomes, and virosomes, which 
present vaccine antigens to the immune system in an efficient manner, and 
control release and storage of antigens to increase specific immune responses.  
The second group is that of immunostimulants which influence the immune 
system by enhancing immune responses to antigens. In particular, they influence 
cytokine production through the activation of MHC molecules, co-stimulatory 
signals, or through related intracellular signaling pathways, such as: Toll-like 
receptor (TLR) agonists (i.e., monophosphoryl lipid A), saponins, and cytokines.  
At present, aluminum salt (alum) adjuvants are the only adjuvants approved by 
the Food and Drug Administration (FDA) in the United States for use in marketed 
vaccines. In Europe, oil in water emulsion is used as an adjuvant in a formulation 
of influenza vaccine, as well as alum adjuvants [5,6] 
Malaria is one of the most severe public health problems worldwide, with the 
most severe and life-threatening forms of the disease caused by Plasmodium 
falciparum [7]. A highly effective vaccine that targets different stages of 
plasmodium infection is necessary as the probability of having a vaccine with just 
one stage target would not be completely effective to control infection.  
Furthermore, this could have a significant impact on malaria-associated morbidity 
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and mortality [8,9]. Two leading protein candidates for the development of a 
malaria vaccine are AMA1 and MSP1. However, this strategy has faced 
significant challenges, yielding limited success so far in clinical trials [10,11]. Very 
high antibody titers are required to confer protective efficacy against the disease 
[12,13]. Therefore, strong vaccine adjuvants that are safe and suitable for clinical 
use are needed in order to achieve protection against the disease. 
Since the development of oral vaccines is a priority, adjuvants able to enhance 
immunogenicity of orally administered antigens are critical. The cholera toxin 
(CT) is a protein whose effects on intestinal epithelial cells is responsible for the 
copious fluid secretion observed in clinical cholera cases. This molecule induces 
immunological memory in gut mucosa, stimulates secretory IgA and plasma IgG, 
and does not induce oral tolerance; however its toxicity makes it prohibitive for 
human use [14,15]. Recently, some adjuvants have received attention due to the 
immunomodulatory responses attributed for their use. CpG, site where cytosine 
(C) lies next to a guanine (G) in the DNA sequence and they are connected by a 
phosphodiester bond (p), present in plant DNA sequences are novel adjuvants, 
promoting the activation of antigen presenting cells including DC, macrophages 
and B cells [16,17].  Pectin is another molecule that showed  immunomodulatory 
activities by stimulating macrophage functions, in human and murine, and 
inducing production of reactive oxygen species, nitric oxide, tumor necrosis factor 
α, and interleukin 6 (IL-6) [18]. In addition, the peptide GK1 from Taenia solium 
has demonstrated promising adjuvant properties by immunostimulating DCs 
[19,20].  
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The aim of this study was to assess the effect of distinct adjuvants on the 
immunogenicity of an oral vaccine formulated with three synthetic malaria 
epitopes, from the blood stage Plasmodium falciparum infection from the AMA1 
and MSP119 protein, since our previous results from chapter 2 had shown the 
potential of the Malchloroplast vaccine using tobacco plants as an expression 
platform and induced a positive immunogenic response. However since there 
was insufficient transplastomic plant tissue available to conduct an oral mouse 
feeding study, we opted to administrate the proposed malaria vaccine via 
subcutaneous injection. In this study, we are assessing the efficacy of the 
proposed malaria candidate antigens response in conjunction with GK1 adjuvant 
as well of other adjuvants to see the feasibility of oral administration using plants 
as a vaccine expression system. 
MATERIALS AND METHODS 
Antigens and adjuvants 
A vaccine, Mvac, comprising the following synthetic peptides: 
QGMLNISQHQCVKKQCPQNS from MSP1 [21],  
DSGSNGKKITCECTKPDSYPLFDGIFCSSSN from MSP1 [22], and 
SKRIKLNDNDDEGNKKIIAPRIFIS from AMA1 (elected by epitope prediction 
tools [23]) was used.  These antigens were synthesized by Genescript 
(Piscataway, NJ) and were used in combination with several adjuvants, including 
the following: Cholera Toxin (CT) as control adjuvant for oral immunization 
(Sigma, St. Louis, MO), Freund’s Complete (FCA) and Incomplete Adjuvants 
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(FIA) (Sigma, St. Louis, MO) as control adjuvant for sc immunization, GK1 
peptide (GYYYPSDPNTFFYAPPYSA, GenScript, Piscataway, NJ), pectin 
isolated from Opuntia plants, or DNA isolated from lettuce plants. All these 
compounds were used at doses of 10 µg, unless noted otherwise.  
Leaf tissues from a hydroponically grown lettuce (bought in local market) were 
used to isolate DNA, and the extraction was performed as described by 
Dellaporta et al. [24].  
Mice immunization assay using synthetic peptides of malaria epitopes 
Immunogenicity of proposed malaria epitopes was evaluated in male BALB/c 
mice (8 weeks of age) that were housed in filter-topped cages, and cared for 
according with federal regulations for animal experiments (NOM-062- ZOO-1999, 
Ministry of Agriculture, Mexico). The immunization protocol was approved by the 
Institutional Animal Care and Use Committee (IACUC).  
Mice were randomly divided into 10 different groups (n = 3) receiving one of the 
following treatments, administered either orally or subcutaneously as indicated: 
(1) Mvac vaccine (Oral), (2) Mvac vaccine and GK1 peptide adjuvant (Oral), (3) 
Mvac and  CT (Oral), (4) Mvac and Lettuce DNA (Oral), (5) Mvac and pectin 
(Oral), (6) Mvac (Subcutaneous), (7) Mvac and GK1 peptide (Subcutaneous), (8) 
Mvac and 2.5µg pectin (Subcutaneous), (9) Mvac and 2.5 µg Lettuce DNA 
(Subcutaneous), and (10) Mvac and Freund’s adjuvant (Subcutaneous), wherein 
the first dose consisted of Freund’s Complete Adjuvant (FCA), while the second 
and third doses consisted of Freund’s Incomplete Adjuvant (FIA).  Three weekly 
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doses were administered to each mice group on days 1, 8, and 15.  Mice were 
bled on days 0, 7, and 14, and then sacrificed on day 22. Serum samples were 
collected from blood extracted following cardiac punctures; while, feces samples 
were collected from the oral groups.  
Evaluation of immune responses 
The antibody content was determined by enzyme linked immunosorbent assay 
(ELISA). Plates were coated with 1 µg/well of MSP1-1, MSP1-2, AMA1 and GK1 
peptides, respectively, diluted in a carbonate/bicarbonate buffer, incubated 
overnight at 4°C, and blocked with 5% fat-free milk dissolved in PBST (100 mM 
NaCl, 10 mM Na2HPO4, and 3 mM KH2PO4; pH 7.2, 5% Tween-20). Plates 
were washed, and PBST diluted serum samples (oral groups 1:10; subcutaneous 
groups 1:20) and fecal samples were added. Triplicate wells of each sample 
were incubated overnight at 4°C. Secondary antibody, horseradish peroxidase 
conjugated goat anti-mouse anti-immunoglobulin G (IgG) antibody (Pierce, 
Rockford, IL) for serum samples or got anti-mouse anti-immunoglobulin A (IgA) 
antibody (Invitrogen, Carlsbad, CA) for feces samples were then added to each 
well, and plates were incubated for 2 h at room temperature. Plates were washed, 
and 0.3 mg/l 2-20- Azino-bis-3 etilbenztiasoline-6-sulphuric acid (ABTS; Sigma, 
St. Louis, MO) substrate solution along with 0.1M H2O2 were added. 
 The OD at 405 nm was recorded using a Multiskan Ascent (Thermo Scientific, 
Waltham, MA) microplate reader.  
Statistical analysis 
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Statistical analyses were conducted using the proc GLM procedures of SAS 
version 9.3 (SAS Inst. Inc., Cary, NC). Group mean comparisons were conducted 
using LSD means and were considered to be significant at p < 0.05 based on 
minimum significant differences from one-way analysis of variance (ANOVA) with 
alpha≤0.05.  
RESULTS 
Mvac vaccine immunogenic responses in mice following oral 
administration  
For assessment of immunogenic responses in test mice by the Mvac vaccine and 
by the different adjuvants, humoral responses elicited against the antigens 
MSP1-1, MSP1-2, and AMA1 were evaluated in orally administrated test mice.  
ELISA assays were conducted by coating plates with the MSP1-1, MSP1-2, 
AMA1, or GK1 synthetic peptides to evaluate IgG serum responses against the 
specific peptides.  
Anti-MSP1-1 IgG serum responses did not exhibit differences between the Mvac 
vaccine (group 1, Mvac) and those groups administered with GK1 peptide (group 
2, Mvac-GK1), CT (group 3, Mvac-CT), lettuce DNA (group 4, Mvac-DNA),and 
pectin (group 5, Mvac-pect.) as adjuvants.  The administration of Mvac and CT, 
as well as, Mvac and lettuce DNA elicited significantly different anti-MSP1-1 IgG 
responses between the day 0 (baseline) and day 22 (one week after the third 
dose administration) (Fig. 3.1). While, no significant anti-MSP1-2 IgG responses 
were elicited among all five oral groups or between those at day 0 and day 22 
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(Fig. 3.2).  This suggested that the MSP1-2 antigen was not antigenic when used 
for the development of an oral vaccine against malaria. 
For the anti-AMA1 IgG serum responses, groups Mvac, Mvac-GK1, and Mvac-
CT exhibited significantly higher responses between the day 0 and day 22 (Fig. 
3.3).  This suggested that the AMA1 peptide was immunogenic when orally 
administered.   However, there were no significant differences observed among 
the three groups of test mice.  The Mvac-GK1 adjuvated group showed 
significantly higher levels of IgG serum responses against the GK1 peptide one 
week following the last administered dose (Fig. 3.4). 
Mvac vaccine immunogenic responses in mice following subcutaneous 
administration 
Response of test mice administered the Mvac vaccine subcutaneously along with 
different adjuvants were assessed to evaluate humoral responses elicited against 
the MSP1-1, MSP1-2, and AMA1 antigens. ELISA assays were conducted by 
coating plates with either the MSP1-1, MSP1-2, AMA1, or GK1 synthetic peptide 
to determine IgG serum responses against the specific peptides. 
Anti-MSP1-1 IgG serum responses of test mice groups Mvac vaccine (group 6, 
Mvac (s.c.)), Mvac and GK1 peptide (group 7,Mvac-GK1 (s.c.)), Mvac and 2.5µg 
pectin (group 8, Mvac-pect. (s.c.)), Mvac and 2.5 µg lettuce DNA (group 9, Mvac-
DNA (s.c.)) and Mvac and Freund’s adjuvant ( group 10, Mvac-FA (s.c.)) did not 
showed significant differences among all five groups; moreover, there were no 
differences observed for responses between day 0 and day 22 (Fig. 3.5).  Similar 
! 71!
results were obtained for anti-MSP1-2 IgG serum responses among all five 
groups and for responses between day 0 and day 22 (Fig. 3.6).  However, test 
mice group 10 showed higher IgG serum responses at day 22 when this was 
used along with an oil-based Freund’s adjuvant (Fig. 3.6). 
When evaluating anti-AMA1 IgG serum responses, significantly higher levels 
were observed between day 0 and day 22 for test mice groups Mvac-GK1 (s.c.) 
and Mvac-DNA (s.c.) (Fig. 3.7).  
When evaluating group 2 test mice, it was found that there were significant 
differences between oral vs. subcutaneous administration of the Mvac vaccine in 
the presence of the GK1 as an adjuvant.  This suggested that the GK1 peptide is 
a good immunogenic adjuvant. Furthermore, anti-GK1 IgG serum elicited 
significant higher responses in test mice group Mvac-GK1 (s.c.), similar response 
observed in the test mice group (Mvac-GK1, oral) (Fig. 3.8). 
Comparisons of immune responses among GK1 adjuvated groups 
The observed responses of anti-AMA1 IgG serum responses in groups Mvac-
GK1 (oral) and Mvac-GK1 (s.c.) have indicated that there were significant 
differences one week after administration of the last dose administrated.  
Furthermore, group Mvac-GK1 (oral) test mice have exhibited significantly higher 
responses than those of group Mvac-GK1 (s.c.) and the group Mvac (oral) (Fig. 
3.9).  This has indicated that Mvac-GK1, administrated orally, is promising as an 
effective vaccine against malaria. Interestingly, higher anti-GK1 antibody levels 
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was induced in the group immunized orally when compared to that immunized 
s.c. (Fig. 3.10). 
Mucosal secretory IgA antibody responses in orally immunized mice 
Evaluation of orally immunized mice IgA responses elicited against the MSP1-1, 
MSP1-2, and AMA1 antigens revealed that there were significant anti-MSP1-1 
mucosal secretory IgA antibodies detected in mice feces at day 22 in groups 
Mvac, Mvac-CT, and Mvac-pect; whereas, there were no significant differences 
between groups Mvac-GK1 and Mvac-DNA (Fig 3.11).  
Similar, results were observed for anti-MSP1-2 and anti-AMA1 mucosal secretory 
IgA antibodies (Fig.3.12 and Fig. 3.13).  
DISCUSSION 
A malaria vaccine that targets multiple parasite growth stages remains the best 
strategy to develop an efficacious vaccine that protects against the disease [25].  
A relevant goal consists on designing a multi-component vaccine with antigens 
specific for two blood stage proteins, MSP1 and AMA1, which have been 
extensively studied [26,27] and proven to be efficacious in conferring protection 
against malaria in different animal models [28,29]. Thus, these leading vaccine 
antigen candidates were selected for this study to assess the immunogenicity in 
BALB/c mice of three peptides from MSP1 and AMA1 (MSP1-1, MSP1-2, and 
AMA1) orally administered along with different adjuvants. 
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In this study, oral immunization of the Mvac vaccine with different adjuvants did 
not elicit good humoral responses against MSP1-1 and MSP1-2 antigens.  
The Mvac vaccine along with the GK1 adjuvant group have shown interesting 
systemic IgG responses against AMA1, thus suggesting that the AMA1 peptide 
could be immunogenic when it is orally administered. 
Furthermore, the Mvac vaccine along with the GK1 and CT adjuvant groups have 
exhibited important systemic IgG responses against AMA1, suggesting that the 
AMA1 peptide could be immunogenic when it is also orally administered. The 
administration of the CT as adjuvant has been considerably studied, and also 
used in development of candidate vaccines, including plant-based vaccines, 
against malaria. Tobacco plants expressing AMA1 and MSP1 elicited good 
immune responses against these antigens in vitro, as well as surviving a cholera 
toxin challenge  [30]. This supported findings obtained in this study, particularly 
for those malaria epitopes used, particularly of the AMA1 antigen. 
The observed anti-AMA1 IgG1 humoral responses of the Mvac vaccine along 
with the GK1 adjuvant, for oral and subcutaneous administration have suggested 
that the combination of the AMA1 antigen and the GK1 is an immunogenic 
pairing.  The AMA1 synthetic peptide selected was predicted using in silico 
analysis in order to identify a sequence that could induce strong humoral 
responses.  The observed higher immunogenic effects due to the presence of the 
GK1 adjuvant have already been reported earlier for other vaccines [19, 20, 30].  
Therefore, findings obtained in this study further confirm these earlier findings. 
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GK1 is a short peptide (18 amino acids) and is rapidly cleared from the human 
body; therefore, it can serve as effective enhancer of vaccine performance, but 
without causing undesirable secondary side effects.  
Segura-Velázquez et al.  [20] have demonstrated that the GK1 adjuvant 
effectively enhances antigen-specific CD4+ T-cell priming, both in vitro and in 
vivo.  In addition, they have reported that GK1 has a direct effect on dendritic 
cells and contributes to the upregulation of co-stimulatory molecules. 
Furthermore, they have also reported on the enhancement of the proliferative 
responses of T cells that specifically recognize an influenza vaccine epitope by 
GK1. 
Comparisons of responses induced by GK1 of anti-AMA1 IgG serum responses 
have suggested that oral administration were higher than those for subcutaneous 
administration.  Therefore, this supports strategies to administer a plant-based 
vaccine, along with the GK1 as an adjuvant, orally rather than subcutaneously.  
This can serve well in delivering the Malchloroplast tobacco-based vaccine 
against malaria developed earlier in this study. Additionally, Taenia solium 
cysticercosis is a parasitic tissue infection caused by larval cysts of the Taenia 
tapeworm. The significant protection induced by GK1 immunization [19], and its 
presence in all developmental stages of T. solium suggest that GK1 is a strong 
candidate in the construction of a synthetic vaccine against cysticercosis, 
conferring dual vaccine action of our proposed plant-based vaccine against 
Malaria and cysticercosis. More studies are needed in order to elucidate if the 
vaccine can be protective of both diseases.   
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Additionally, further studies should be conducted to better understand the 
induced immune response of GK1 and CT groups, and determine their roles in 
lymphocyte proliferation, CD4+ T cells, and cytokines. 
On the other hand, pectin exerted adjuvant effects in terms of the sIgA responses 
against MSP1 and AMA1 peptides. However, since malaria is transmitted by the 
bite of the vector, humoral systemic responses are the priority to confer 
immunoprotection. Thus, the most promising adjuvant effect found in this study is 
that exerted by GK1.  
The results obtained in this study provide insights of immunogenic responses of 
different adjuvants and candidate malaria antigens.  
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FIGURES 
 
 
 
 
 
Figure 3.1. Anti-MSP1-1 IgG serum responses elicited in BALB/c mice. Test 
animal groups were dosed orally with Mvac vaccine adjuvant with 10 µg of  GK1, 
CT,  DNA and Pectin. After dilution (sera 1:10), samples were analyzed by ELISA. 
Mean OD values ± SD from 405 nm each experimental group (*P < 0.05 Day 0 
vs. Day 22 per group). 
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Figure 3.2. Anti-MSP1-2 IgG serum responses elicited in BALB/c mice. Test 
animal groups were dosed orally with Mvac vaccine adjuvant with 10 µg of GK1 , 
CT,  DNA and Pectin. After dilution (sera 1:10), samples were analyzed by ELISA. 
Mean OD values ± SD from 405 nm each experimental group (*P < 0.05 Day 0 
vs. Day 22 per group). 
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Figure 3.3. Anti-AMA1 IgG serum responses elicited in BALB/c mice. Test 
animal groups were dosed orally with Mvac vaccine adjuvant with 10 µg of  GK1, 
CT, DNA and Pectin. After dilution (sera 1:10), samples were analyzed by ELISA. 
Mean OD values ± SD from 405 nm each experimental group (*P < 0.05 Day 0 
vs. Day 22 per group). 
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Figure 3.4. Anti-GK1 IgG serum responses elicited in BALB/c mice that received 
Mvac vaccine with GK1 as adjuvant. After dilution (sera 1:10), samples were 
analyzed by ELISA. Mean OD values ± SD from 405 nm experimental group (*P 
< 0.05). 
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Figure 3.5. Anti-MSP1-1 IgG serum responses elicited in BALB/c mice. Test 
animal groups were dosed subcutaneously with Mvac vaccine, Mvac vaccine 
adjuvant with 10 µg of  GK1, 2.5 µg Pectin, 2.5µg DNA and Freund adjuvant. 
After dilution (sera 1:20), samples were analyzed by ELISA. Mean OD values ± 
SD from 405 nm each experimental group (*P < 0.05 Day 0 vs. Day 22 per 
group). 
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Figure 3.6. Anti-MSP1-2 IgG serum responses elicited in BALB/c mice. Test 
animal groups were dosed subcutaneously with Mvac vaccine (G6); Mvac 
vaccine adjuvant with 10 µg of GK1, 2.5 µg Pectin, 2.5µg DNA and Freund 
adjuvant. After dilution (sera 1:20), samples were analyzed by ELISA. Mean OD 
values ± SD from 405 nm each experimental group (*P < 0.05 Day 0 vs. Day 22 
per group). 
 
 
 
 
 
* 
0!
0.2!
0.4!
0.6!
0.8!
1!
1.2!
1.4!
1.6!
Mvac! Mvac;GK1! Mvac;Pect! Mvac;DNA! Mvac;FA!
O
D4
05
nm
#
MSP112#
Day!0!
Day!22!
! 86!
 
 
 
 
Figure 3.7. Anti-AMA1 IgG serum responses elicited in BALB/c mice. Test 
animal groups were dosed subcutaneously with Mvac vaccine (G6); Mvac 
vaccine adjuvant with 10 µg of GK1, 2.5 µg Pectin, 2.5µg DNA and Freund 
adjuvant. After dilution (sera 1:20), samples were analyzed by ELISA. Mean OD 
values ± SD from 405 nm each experimental group (*P < 0.05 Day 0 vs. Day 22 
per group). 
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Figure 3.8. Anti-GK1 IgG serum responses elicited in BALB/c mice that received 
Mvac vaccine with GK1 as adjuvant. After dilution (sera 1:20), samples were 
analyzed by ELISA. Mean OD values ± SD from 405 nm experimental group (*P 
< 0.05). 
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Figure 3.9. ELISA anti-AMA1 IgG serum responses elicited in BALB/c mice 
comparison between groups that received Mvac vaccine and GK1 adjuvant. 
Mean OD values ± SD from 405 nm each experimental group (*P< 0.05 between 
groups). 
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Figure 3.10. ELISA anti-GK1 IgG serum responses elicited in BALB/c mice 
comparison between groups that received Mvac vaccine and GK1 adjuvant. 
Mean OD values ± SD from 405 nm each experimental group (*P < 0.05 between 
groups). 
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Figure 3.11. ELISA anti-MSP1-1 fecal IgA responses elicited in BALB/c mice. 
Test animal groups were dosed orally with Mvac vaccine adjuvant with 10 µg of 
GK1, CT, DNA and Pectin. After dilution (sera 1:10), samples were analyzed by 
ELISA. Mean OD values ± SD from 405 nm each experimental group (P < 0.05). 
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Figure 3.12. ELISA anti-MSP1-2 fecal IgA responses elicited in BALB/c mice. 
Test animal groups were dosed orally with Mvac vaccine adjuvant with 10 µg of 
GK1, CT, DNA and Pectin. Mean OD values ± SD from 405 nm each 
experimental group (P < 0.05). 
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Figure 3.13. ELISA anti-AMA1 fecal IgA responses elicited in BALB/c mice. Test 
animal groups were dosed orally with Mvac vaccine adjuvant with 10 µg of GK1, 
CT, DNA and Pectin. Mean OD values ± SD from 405 nm each experimental 
group (P < 0.05). 
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Figure 3.14. ELISA anti-GK1 fecal IgA responses elicited in BALB/c mice. Test 
animal groups were dosed orally with Mvac vaccine adjuvant with 10 µg of GK1, 
CT, DNA and Pectin. Mean OD values ± SD from 405 nm each experimental 
group (P < 0.05). 
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CHAPTER 4 
Summary And Future Directions 
Malaria, caused by Plasmodium parasites, remains a global public health 
problem in the tropical world.  An estimated 3.2 billion people are at risk annually, 
and 200 million cases of malaria infections occur globally [1].  Developing an 
effective vaccine against this disease is urgently needed in order to protect 
vulnerable populations, including infants, children under 5 years of age, pregnant 
women, and immunocompromised individuals, among others.  An ideal vaccine 
must be designed as a multicomponent vaccine with a combination of antigens of 
the different parasite life cycle infection stages. Also, this vaccine should be safe, 
proven effective, and produced at low-cost. Conventional approaches for vaccine 
production are expensive and involve a complex production and purification 
methods.  In addition, the cost of such a vaccine increases with the costs 
associated with the use of adjuvants and refrigeration for storage.  Using plants 
as bioreactors for the production of vaccines is a viable alternative as it has many 
advantages, including low-cost of production, lack of contamination with 
mammalian pathogens, easy administration, longer shelf life, and no need for 
refrigeration [2,3]. 
In this study, a chloroplast plant-based vaccine against malaria has been 
developed.  This vaccine is comprised of the two leading antigen candidates in 
the blood stage life cycle of the Plasmodium falciparum along with a GK1 peptide 
adjuvant.  The expression of the AMA1 and MSP119 malaria antigens has been 
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successfully demonstrated in transplastomic tobacco plants using RT-PCR, and 
the protein levels were determined using Western blots ELISA analysis.  Sera 
from P. falciparum infected patients have exhibited immunoreactivity for all four 
transplastomic lines tested.  Furthermore, test mice immunized with MC9T1S16 
line plant extracts developed antibody responses against AMA1, MSP1, and the 
adjuvant GK1.  In addition, different responses were observed among mice 
immunized with the MC9T1S16 line and those treated with non-transformed plant 
tissues, following administration of the final dose. Upon administration of a 
peptide boost with the malaria antigens, no significant differences were detected.  
All these findings together suggest that the recombinant tobacco-derived 
Malchloroplast antigens induce systemic antibody responses in test mice. These 
transplastomic plant lines can serve as a low-cost and efficient platform for 
production of a multiepitopic malaria proteins and retaining their antigenic 
determinants. For future studies, a parasite lethal challenge should be conducted 
to determine whether an effective protective immune response is induced by 
testing the response and survival of the animals. 
Subsequently, to further elucidate the immunogenicity of the selected antigens 
along with different adjuvants administrated in test mice via oral and 
subcutaneous administration. Three synthetic peptides from AMA1 and MSP1 
antigens forming a designated Mvac vaccine were assessed in combination with 
different adjuvants, including GK1 peptide, CT, lettuce DNA, pectin, and Freund’s 
adjuvant.  The combination of the Mvac vaccine and the GK1 induced higher 
anti-AMA1 IgG humoral responses for both oral and subcutaneous groups.  This 
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suggested that the administration of AMA1 antigen and GK1 is a good 
immunogenic pairing. The effects produced by GK1 confirm earlier findings 
reporting that GK1 induced high levels of immunogenic protection [4,5,6]. 
Moreover, tested mice with the Mvac vaccine along with the GK1 demonstrated 
that oral administration resulted in higher anti-AMA1 IgG responses, thus further 
suggesting that oral administration of the candidate vaccine will elicit higher 
immunogenic responses. Future studies should be conducted to characterize 
those induced responses of the GK1 adjuvant along with the Mvac vaccine by 
conducting lymphocyte proliferation determination using cytometer analysis and 
study CD4+ T cells, as well as expression levels of cytokines. 
In conclusion, a multi-component plant-based vaccine against malaria expressing 
AMA1 and MSP1 antigens, and the GK1 peptide has the potential to serve as a 
viable and promising low-cost vaccine. In addition, oral administration of a 
vaccine with GK1 has promising immunogenic effects, and that a plant-based 
vaccine administered orally can be effective. 
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